1. OP0149 VISUAL LOSS IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB. (2nd June 2020) Authors: Amsler, J.; Kysela, I.; Christ, L.; Tappeiner, C.; Seitz, L.; Scholz, G.; Kollert, F.; Reichenbach, S.; Villiger, P. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB801 is a potent and selective AXL inhibitor that demonstrates significant anti-tumor activity in combination with standard of care therapeutics. (October 2022) Authors: Paprcka, S.; Sridhar, S.; Goshayeshi, A.; Park, E.; Liu, S.; Flores, R.; Rocha, L.; Miles, D.; Lamani, M.; Cho, S.; Wang, N.; Guan, Y.; Chandrasekar, S.; Kushwaha, R.; Jafri, S.; Kaplan, A.; Stagnaro, E.; Seitz, L.; Kline, J.; Fernandez-Salas, E. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. HIF-2α inhibitor AB521 modulates erythropoietin levels in healthy volunteers following a single oral dose. (October 2022) Authors: Liao, K.; Foster, P.; Seitz, L.; Cheng, T.; Gauthier, K.; Lawson, K.; Jin, L.; Paterson, E. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy. (March 2018) Authors: Schindler, U.; Seitz, L.; Ashok, D.; Piovesan, D.; Tan, J.; DiRenzo, D.; Yin, F.; Leleti, M.; Rosen, B.; Miles, D.; Jin, L.; Park, T.; Young, S.; Soriano, F.; Rieger, A.; Karakunnel, J.; Sharif, E.; Powers, J.P.; Walters, M.J. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 1 Page Start: S14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗